Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic compositions for treating ocular hypertension

A technology of compounds and mixtures, which can be used in drug combinations, medical preparations containing active ingredients, organic chemistry, etc., and can solve problems such as unsatisfactory efficacy and side effects, and increased

Inactive Publication Date: 2008-04-30
SCHERING AG
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] There are some therapies for glaucoma and elevated intraocular pressure, and the efficacy and side effect profiles of these agents are suboptimal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic compositions for treating ocular hypertension
  • Ophthalmic compositions for treating ocular hypertension
  • Ophthalmic compositions for treating ocular hypertension

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0092]

[0093] A 500 ml flask was charged with 336 mmol (13.44 g; 60%) of sodium hydride. 150 ml of DMSO was added under an argon atmosphere, and then 32 ml of ethyl cyanoacetate (2.2 eq; 352 mmol) were added dropwise at 50°C. After complete addition, the reaction was allowed to warm to room temperature over 1 hour. 30 g of the nitrobenzene derivative (160 mmol) were added in powder form. The reaction mixture was heated at 90° C. for 8 hours in a closed system. Acidification and standard work-up gave a crude oily residue which was purified on a silica gel column to give 39 g of the desired crystalline product, which was decarboxylated to give the following benzonitrile. 38 g of SM obtained above were dissolved in 400 ml of 1N sodium carbonate. The homogeneous solution was stirred at room temperature for two days. Thin layer chromatography analysis indicated that the reaction was complete. The reaction mixture was acidified and extracted with ethyl acetate (100ml×4). ...

preparation Embodiment 2

[0096]

[0097] 10 g of the benzonitrile derivative were dissolved in 20 ml of THF and then diluted with 50 ml of methanol. The reaction mixture was transferred to a pressure tube, palladium-carbon (10% by weight / 10 mol%) was added, and the reaction mixture was hydrogenated at 40 psi. After the amount of hydrogen necessary to reduce the nitro group has been consumed, the reaction is stopped. TLC analysis indicated that the spots had been transformed spots. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated to a solid and used directly in the next step. The crude aniline derivative (52 mmol) was dissolved / suspended in 2N hydrochloric acid (150 ml), cooled to 5°C, and then 5.4 g of sodium nitrite in 10 ml of aqueous solution was added. The reaction mixture was stirred for 1 hour and gradually warmed to room temperature. TLC analysis showed that SM had been consumed and a new spot was formed. The reaction mixture was extracted with...

preparation Embodiment 3

[0099]

[0100] Weigh 4.15 g of indazole and the azeotropic water and 2 toluene (100 ml) washes, and remove the toluene azeotrope by rotary evaporation. Dry well under high vacuum and flush with argon. Dissolve in 40 ml dry THF and 92 ml dry ether under argon atmosphere. Cool to 5 °C in an ice-water bath. Charge 3 equivalents of isopropylmagnesium chloride ((6 ml) in 2M THF) and stir at room temperature for 0.5 hours. 1N Hydrochloric acid (240ml) was added carefully and stirred for 1 hour. The progress of the reaction was monitored by thin layer chromatography. Extraction with ethyl acetate and rotary evaporation yielded the desired product.

[0101] LCMS[M+H]=219

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Description

Background technique [0001] Glaucoma is a degenerative disease of the eye in which the intraocular pressure is too high for normal eye function. The result can damage the optic nerve endings and cause irreversible damage to visual function. If left untreated, glaucoma may eventually lead to blindness. Ocular hypertension, or elevated intraocular pressure without damage to the optic nerve endings or characteristic glaucomatous visual field loss, is now considered by most ophthalmologists to be present only in the earliest stages of glaucoma onset. [0002] There are several therapies for glaucoma and elevated intraocular pressure, and the efficacy and side effect profiles of these agents are suboptimal. Potassium channel blockers have recently been found to lower intraocular pressure in the eye and thus may offer another approach to treating ocular hypertension and the corresponding degeneration of the eye condition. Blockage of potassium channels reduces fluid secretion and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D231/56A61K31/416A61P27/06
Inventor J·B·多赫尔蒂M·-H·陈L·刘S·R·纳塔拉彦R·M·泰内博尔
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com